Genomenon, an Ann Arbor-based company that specializes in genomic data search capabilities, has partnered with Massachusetts’ Veritas, a whole genome sequencing company, to allow consumers to more easily interpret results from genetic testing.
While the most critical hurdle for consumers was once the cost of genetic testing, now consumers have the ability to interpret results efficiently and at scale. Such testing is now available for under $1,000.
“Our goal is to empower millions of consumers to access their own genomic information and use it throughout their lives,” says Mirza Cifric, founder and CEO of Veritas. “This will not happen without applying the most advanced machine learning and AI tools to large genomic datasets. We are delighted to partner with Genomenon to make this happen.”
As part of the partnership, the two companies will collaborate to develop the next-generation literature prioritization engine through proprietary genomic language processing, machine learning, and artificial intelligence tools.
The engine process will follow the American College of Medical Genetics and Association for Medical Pathology variant classification frameworks. Veritas will also integrate Genomenon’s Mastermind Genomic Search Engine software to its current workflow and interpretation tools, and the clinical variant science team at Veritas will advise Genomenon’s product development team with ongoing requirements and product refinements.
The two companies will work to address two issues: Identification and prioritization of relevant literature to ensure proper variant classification efficiently and at scale, and create an efficient way to alert and update variant classifications as new knowledge arises.
“Variant classification sits at the center of the genomic revolution,” says Mike Klein, CEO of Genomenon. “Creating tools and standards requires the best and most experienced minds in the field. We’re excited to be working with the Veritas team at the forefront of personal genomics. We look forward to radically moving the field forward through our collective expertise and variant interpretation tools.”
Genomenon connects patient genomic data with evidence from scientific literature to diagnose and deliver better patient outcomes. It offers a genomic search engine. Veritas, or The Genome Company, screens the majority of individuals’ DNA through whole genome sequencing to provide insights and help people understand their genetics.